Blue Robert C, Lo Grace C, Kim Edward, Patel Rahul S, Scott Nowakowski F, Lookstein Robert A, Fischman Aaron M
Interventional Radiology Section, Department of Radiology, Icahn School of Medicine at Mount Sinai, Box 1234, One Gustave Levy Place, New York, NY, 10029, USA.
Cardiovasc Intervent Radiol. 2016 Jun;39(6):935-9. doi: 10.1007/s00270-015-1249-2. Epub 2015 Dec 1.
A complication of transjugular intrahepatic portosystemic shunts (TIPS) placement is refractory portosystemic encephalopathy (PSE) often requiring TIPS reduction. We report the results of a "sheath control technique" utilizing constraining sheaths during deployment of polytetrafluoroethylene (PTFE)-covered balloon-expandable stents, minimizing stent migration, and providing additional procedural control.
TIPS reduction was performed in 10 consecutive patients for PSE using Atrium iCast covered stents (Atrium Maquet Getinge Group, Germany). Within the indwelling TIPS stent, a 9 mm × 59 mm iCast stent was deployed with 2 cm exposed from the sheath's distal end and the majority of the stent within the sheath to create the distal hourglass shape. During balloon retraction, the stent was buttressed by the sheath. The proximal portion of the stent was angioplastied to complete the hourglass configuration, and the central portion of the stent was dilated to 5 mm. Demographics, pre- and post-procedure laboratory values, and outcomes were recorded.
Ten patients underwent TIPS reduction with 100 % technical success. There was no stent migration during stent deployment. All patients experienced initial improvement of encephalopathy. One patient ultimately required complete TIPS occlusion for refractory PSE, and another developed TIPS occlusion 36 days post-procedure. There was no significant trend toward change in patients' MELD scores immediately post-procedure or at 30 days (p = 0.46, p = 0.47, respectively).
TIPS reduction using Atrium iCast PTFE balloon-expandable stents using the "sheath control technique" is safe and effective, and minimizes the risk of stent migration.
经颈静脉肝内门体分流术(TIPS)置入的一个并发症是难治性门体性脑病(PSE),常需要缩小TIPS。我们报告了一种“鞘管控制技术”的结果,该技术在部署聚四氟乙烯(PTFE)覆膜球囊可扩张支架期间使用约束鞘管,将支架移位降至最低,并提供额外的手术控制。
连续10例因PSE行TIPS缩小术的患者使用Atrium iCast覆膜支架(德国Atrium Maquet Getinge集团)。在留置的TIPS支架内,置入一个9mm×59mm的iCast支架,使其2cm暴露于鞘管远端之外,且大部分支架位于鞘管内,以形成远端沙漏形。在球囊回撤过程中,支架由鞘管支撑。对支架近端进行血管成形术以完成沙漏形结构,并将支架中央部分扩张至5mm。记录患者的人口统计学资料、术前和术后实验室检查值以及结果。
10例患者接受TIPS缩小术,技术成功率达100%。支架置入过程中无支架移位。所有患者的脑病均有初始改善。1例患者最终因难治性PSE需要完全闭塞TIPS,另1例患者在术后36天发生TIPS闭塞。术后即刻或30天时患者的终末期肝病模型(MELD)评分无显著变化趋势(分别为p = 0.46,p = 0.47)。
使用“鞘管控制技术”,采用Atrium iCast PTFE球囊可扩张支架进行TIPS缩小术是安全有效的,并将支架移位风险降至最低。